Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Notch1 regulates the initiation of metastasis and self-renewal of Group 3 medulloblastoma.

Kahn SA, Wang X, Nitta RT, Gholamin S, Theruvath J, Hutter G, Azad TD, Wadi L, Bolin S, Ramaswamy V, Esparza R, Liu KW, Edwards M, Swartling FJ, Sahoo D, Li G, Wechsler-Reya RJ, Reimand J, Cho YJ, Taylor MD, Weissman IL, Mitra SS, Cheshier SH.

Nat Commun. 2018 Oct 8;9(1):4121. doi: 10.1038/s41467-018-06564-9. Erratum in: Nat Commun. 2018 Nov 2;9(1):4651.

2.

FoxG1 interacts with Bmi1 to regulate self-renewal and tumorigenicity of medulloblastoma stem cells.

Manoranjan B, Wang X, Hallett RM, Venugopal C, Mack SC, McFarlane N, Nolte SM, Scheinemann K, Gunnarsson T, Hassell JA, Taylor MD, Lee C, Triscott J, Foster CM, Dunham C, Hawkins C, Dunn SE, Singh SK.

Stem Cells. 2013 Jul;31(7):1266-77. doi: 10.1002/stem.1401.

3.

Polycomb group gene BMI1 controls invasion of medulloblastoma cells and inhibits BMP-regulated cell adhesion.

Merve A, Dubuc AM, Zhang X, Remke M, Baxter PA, Li XN, Taylor MD, Marino S.

Acta Neuropathol Commun. 2014 Jan 24;2:10. doi: 10.1186/2051-5960-2-10.

4.

Foretinib is effective therapy for metastatic sonic hedgehog medulloblastoma.

Faria CC, Golbourn BJ, Dubuc AM, Remke M, Diaz RJ, Agnihotri S, Luck A, Sabha N, Olsen S, Wu X, Garzia L, Ramaswamy V, Mack SC, Wang X, Leadley M, Reynaud D, Ermini L, Post M, Northcott PA, Pfister SM, Croul SE, Kool M, Korshunov A, Smith CA, Taylor MD, Rutka JT.

Cancer Res. 2015 Jan 1;75(1):134-46. doi: 10.1158/0008-5472.CAN-13-3629. Epub 2014 Nov 12.

5.

PDGF-D promotes cell growth, aggressiveness, angiogenesis and EMT transformation of colorectal cancer by activation of Notch1/Twist1 pathway.

Chen J, Yuan W, Wu L, Tang Q, Xia Q, Ji J, Liu Z, Ma Z, Zhou Z, Cheng Y, Shu X.

Oncotarget. 2017 Feb 7;8(6):9961-9973. doi: 10.18632/oncotarget.14283.

6.

Survivin as a therapeutic target in Sonic hedgehog-driven medulloblastoma.

Brun SN, Markant SL, Esparza LA, Garcia G, Terry D, Huang JM, Pavlyukov MS, Li XN, Grant GA, Crawford JR, Levy ML, Conway EM, Smith LH, Nakano I, Berezov A, Greene MI, Wang Q, Wechsler-Reya RJ.

Oncogene. 2015 Jul;34(29):3770-9. doi: 10.1038/onc.2014.304. Epub 2014 Sep 22.

7.

ATOH1 Promotes Leptomeningeal Dissemination and Metastasis of Sonic Hedgehog Subgroup Medulloblastomas.

Grausam KB, Dooyema SDR, Bihannic L, Premathilake H, Morrissy AS, Forget A, Schaefer AM, Gundelach JH, Macura S, Maher DM, Wang X, Heglin AH, Ge X, Zeng E, Puget S, Chandrasekar I, Surendran K, Bram RJ, Schüller U, Talyor MD, Ayrault O, Zhao H.

Cancer Res. 2017 Jul 15;77(14):3766-3777. doi: 10.1158/0008-5472.CAN-16-1836. Epub 2017 May 10.

8.

miR-192 suppresses leptomeningeal dissemination of medulloblastoma by modulating cell proliferation and anchoring through the regulation of DHFR, integrins, and CD47.

Yang SY, Choi SA, Lee JY, Park AK, Wang KC, Phi JH, Koh EJ, Park WY, Park SH, Hwang DW, Jung HW, Kim SK.

Oncotarget. 2015 Dec 22;6(41):43712-30. doi: 10.18632/oncotarget.6227.

9.

Long noncoding RNA CCAT1 promotes cell proliferation and metastasis in human medulloblastoma via MAPK pathway.

Gao R, Zhang R, Zhang C, Zhao L, Zhang Y.

Tumori. 2018 Jan-Feb;104(1):43-50. doi: 10.5301/tj.5000662.

PMID:
28777430
10.

Convergence of BMI1 and CHD7 on ERK Signaling in Medulloblastoma.

Badodi S, Dubuc A, Zhang X, Rosser G, Da Cunha Jaeger M, Kameda-Smith MM, Morrissy AS, Guilhamon P, Suetterlin P, Li XN, Guglielmi L, Merve A, Farooq H, Lupien M, Singh SK, Basson MA, Taylor MD, Marino S.

Cell Rep. 2017 Dec 5;21(10):2772-2784. doi: 10.1016/j.celrep.2017.11.021.

11.

PI-3K Inhibitors Preferentially Target CD15+ Cancer Stem Cell Population in SHH Driven Medulloblastoma.

Singh AR, Joshi S, Zulcic M, Alcaraz M, Garlich JR, Morales GA, Cho YJ, Bao L, Levy ML, Newbury R, Malicki D, Messer K, Crawford J, Durden DL.

PLoS One. 2016 Mar 3;11(3):e0150836. doi: 10.1371/journal.pone.0150836. eCollection 2016.

12.

CAT3, a novel agent for medulloblastoma and glioblastoma treatment, inhibits tumor growth by disrupting the Hedgehog signaling pathway.

Chen J, Lv H, Hu J, Ji M, Xue N, Li C, Ma S, Zhou Q, Lin B, Li Y, Yu S, Chen X.

Cancer Lett. 2016 Oct 28;381(2):391-403. doi: 10.1016/j.canlet.2016.07.030. Epub 2016 Aug 2.

PMID:
27495899
13.

Mechanism of action and therapeutic efficacy of Aurora kinase B inhibition in MYC overexpressing medulloblastoma.

Diaz RJ, Golbourn B, Faria C, Picard D, Shih D, Raynaud D, Leadly M, MacKenzie D, Bryant M, Bebenek M, Smith CA, Taylor MD, Huang A, Rutka JT.

Oncotarget. 2015 Feb 20;6(5):3359-74.

14.

Inhibition of nuclear factor kappa-B signaling reduces growth in medulloblastoma in vivo.

Spiller SE, Logsdon NJ, Deckard LA, Sontheimer H.

BMC Cancer. 2011 Apr 14;11:136. doi: 10.1186/1471-2407-11-136.

15.

BET bromodomain protein inhibition is a therapeutic option for medulloblastoma.

Henssen A, Thor T, Odersky A, Heukamp L, El-Hindy N, Beckers A, Speleman F, Althoff K, Schäfers S, Schramm A, Sure U, Fleischhack G, Eggert A, Schulte JH.

Oncotarget. 2013 Nov;4(11):2080-95.

16.

β-Catenin-Gli1 interaction regulates proliferation and tumor growth in medulloblastoma.

Zinke J, Schneider FT, Harter PN, Thom S, Ziegler N, Toftgård R, Plate KH, Liebner S.

Mol Cancer. 2015 Feb 3;14:17. doi: 10.1186/s12943-015-0294-4.

17.

Polycomb genes expression as a predictor of poor clinical outcome in children with medulloblastoma.

Zakrzewska M, Zakrzewski K, Grešner SM, Piaskowski S, Zalewska-Szewczyk B, Liberski PP.

Childs Nerv Syst. 2011 Jan;27(1):79-86. doi: 10.1007/s00381-010-1260-5. Epub 2010 Aug 18.

18.

Deconstruction of medulloblastoma cellular heterogeneity reveals differences between the most highly invasive and self-renewing phenotypes.

Morrison LC, McClelland R, Aiken C, Bridges M, Liang L, Wang X, Di Curzio D, Del Bigio MR, Taylor MD, Werbowetski-Ogilvie TE.

Neoplasia. 2013 Apr;15(4):384-98.

19.

Loss of Mel-18 enhances breast cancer stem cell activity and tumorigenicity through activating Notch signaling mediated by the Wnt/TCF pathway.

Won HY, Lee JY, Shin DH, Park JH, Nam JS, Kim HC, Kong G.

FASEB J. 2012 Dec;26(12):5002-13. doi: 10.1096/fj.12-209247. Epub 2012 Sep 5.

PMID:
22954590
20.

IDO1 involvement in mTOR pathway: a molecular mechanism of resistance to mTOR targeting in medulloblastoma.

Folgiero V, Miele E, Carai A, Ferretti E, Alfano V, Po A, Bertaina V, Goffredo BM, Benedetti MC, Camassei FD, Cacchione A, Locatelli F, Mastronuzzi A.

Oncotarget. 2016 Aug 16;7(33):52900-52911. doi: 10.18632/oncotarget.9284.

Supplemental Content

Support Center